[go: up one dir, main page]

RU98118568A - TRIARY CONNECTIONS - Google Patents

TRIARY CONNECTIONS

Info

Publication number
RU98118568A
RU98118568A RU98118568/04A RU98118568A RU98118568A RU 98118568 A RU98118568 A RU 98118568A RU 98118568/04 A RU98118568/04 A RU 98118568/04A RU 98118568 A RU98118568 A RU 98118568A RU 98118568 A RU98118568 A RU 98118568A
Authority
RU
Russia
Prior art keywords
methoxy
biphenyl
phenyl
aryl
pyridine
Prior art date
Application number
RU98118568/04A
Other languages
Russian (ru)
Other versions
RU2194035C2 (en
Inventor
Уилльям Мэнли Пол
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9604926.7A external-priority patent/GB9604926D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU98118568A publication Critical patent/RU98118568A/en
Application granted granted Critical
Publication of RU2194035C2 publication Critical patent/RU2194035C2/en

Links

Claims (12)

1. (4-окси-3-(арил)фенил)азарильное соединение или (4-окси-3-(арил)фенил)арилкарбонилоксисоединение в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли, предназначенное для применения в качестве фармацевтического препарата.1. (4-hydroxy-3- (aryl) phenyl) azaryl compound or (4-hydroxy-3- (aryl) phenyl) arylcarbonyloxy compound in free form or in the form of a pharmaceutically acceptable acid addition salt, intended for use as a pharmaceutical preparation . 2. Фармацевтическая композиция, содержащая (4-окси-3-(арил)фенил)-азарильное соединение или (4-окси-3-(арил)фенил)арилкарбонилоксисоединение в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли. 2. A pharmaceutical composition comprising a (4-hydroxy-3- (aryl) phenyl) -azaryl compound or (4-hydroxy-3- (aryl) phenyl) arylcarbonyloxy compound in free form or in the form of a pharmaceutically acceptable acid addition salt. 3. Применение (4-окси-3-(арил)фенил)азарильного соединения или (4-окси-3-(арил)фенил)арилкарбонилоксисоединения в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли при изготовлении лекарственного средства, предназначенного для лечения или профилактики воспалительного заболевания. 3. The use of (4-hydroxy-3- (aryl) phenyl) azaryl compound or (4-hydroxy-3- (aryl) phenyl) arylcarbonyloxy compounds in free form or in the form of a pharmaceutically acceptable acid additive salt in the manufacture of a medicine intended for treating or preventing inflammatory disease. 4. Способ лечения или профилактики воспалительного заболевания, включающий введение эффективного количества (4-окси-3-(арил)фенил)-азарильного соединения или (4-окси-3-(арил)фенил)арилкарбонилоксисоединения в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли пациенту, нуждающемуся в такой терапии. 4. A method of treating or preventing an inflammatory disease, comprising administering an effective amount of (4-hydroxy-3- (aryl) phenyl) -azaryl compound or (4-hydroxy-3- (aryl) phenyl) arylcarbonyloxy compounds in free form or in pharmaceutically acceptable form. acid additive salt to a patient in need of such therapy. 5. (4-окси-3-(арил)фенил)азарильное соединение или (4-окси-3-(арил)фенил)арилкарбонилоксисоединение в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли, при условии: что 3-арильный фрагмент не обозначает незамещеный фенил, когда фрагмент арилкарбонилокси обозначает фенил-4-карбоновую кислоту или фенил-4-метилкарбоксилат, или азарильный фрагмент обозначает 5-метилтиазол-2-ил, или при условии, что 3-арильный фрагмент не обозначает незамещенный фенил или 2-метоксифен-1-ил, когда азарильный фрагмент обозначает незамещенный 2-хинолин или 2-хинолин, замещенный метилом или фенилом в положении 3 и/или карбоксигруппой в положении 4. 5. (4-hydroxy-3- (aryl) phenyl) azaryl compound or (4-hydroxy-3- (aryl) phenyl) arylcarbonyloxy compound in free form or in the form of a pharmaceutically acceptable acid addition salt, provided that: 3-aryl the moiety does not denote unsubstituted phenyl, when the arylcarbonyloxy moiety is phenyl-4-carboxylic acid or phenyl-4-methylcarboxylate, or the asaryl moiety is 5-methylthiazol-2-yl, or with the proviso that the 3-aryl moiety does not mean unsubstituted phenyl or 2 -methoxyphen-1-yl, when the azaryl moiety is unsubstituted ny 2-quinoline or 2-quinoline substituted by methyl or phenyl at position 3 and / or by carboxy at position 4. 6. (4-окси-3-(арил)фенил)азарильное соединение по п. 1 или 5. 6. (4-hydroxy-3- (aryl) phenyl) azaryl compound according to claim 1 or 5. 7. (4-окси-3-(арил)фенил)арилкарбонилоксисоединение по п. 1 или 5. 7. (4-hydroxy-3- (aryl) phenyl) arylcarbonyloxy compound according to claim 1 or 5. 8. Соединение по пп. 1, 5, 6 или 7 формулы Ia или формулы Ib:
Figure 00000001

Figure 00000002

где в формуле Ia W обозначает N или C-CO-R,
где R обозначает ОН, О-С1-С6алкил или NR3R4,
где R3 и R4, которые могут иметь одинаковые или различные значения, обозначают Н или С1-С6алкил, или
в формуле Ib Az обозначает азарильную группу, содержащую один или несколько атомов азота, такую, как хинолин, изохинилин, индол, имидазопиридин, например, имидазо[1,2-а] пиридин, и в обеих формулах Iа и Ib R1 обозначает С1-С4алкил, предпочтительно метил; R2 обозначает фенильный фрагмент, например, формулы II
Figure 00000003

где R5 и R6 независимо друг от друга обозначают Н, нитро, галоген (например, хлор), трифторметил, С1-С4алкокси, циано или фенокси; или R5 и R6 вместе образуют мостик, имеющий длину 3-5 атомов, где атомы мостика выбирают из группы, включающей S, О, N и С, например, -ОСН2О-, или пропилен; или R2 обозначает 2,5-циклогексадиен-3,4-илидин-1-иловый фрагмент, например, формулы III
Figure 00000004

где R7 и R8 вместе образуют ароматический мостик, имеющий длину 3-5 атомов, где атомы мостика выбирают из группы, включающей S, О, N и С, например, =N-O-N=;
в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли.8. Connection on PP. 1, 5, 6 or 7 of formula Ia or formula Ib:
Figure 00000001

Figure 00000002

where in formula Ia W denotes N or C-CO-R,
where R is OH, OC 1 -C 6 alkyl or NR 3 R 4 ,
where R 3 and R 4 , which may have the same or different meanings, are H or C 1 -C 6 alkyl, or
in formula Ib, Az means an asaric group containing one or more nitrogen atoms, such as quinoline, isoquiniline, indole, imidazopyridine, for example, imidazo [1,2-a] pyridine, and in both formulas Ia and Ib R 1 is C 1 -C 4 alkyl, preferably methyl; R 2 denotes a phenyl fragment, for example, of formula II
Figure 00000003

where R 5 and R 6 independently of one another denote H, nitro, halogen (for example, chlorine), trifluoromethyl, C 1 -C 4 alkoxy, cyano or phenoxy; or R 5 and R 6 together form a bridge having a length of 3-5 atoms, where the atoms of the bridge are selected from the group consisting of S, O, N and C, for example, -OCH 2 O-, or propylene; or R 2 denotes a 2,5-cyclohexadiene-3,4-ylidin-1-yl fragment, for example, of formula III
Figure 00000004

where R 7 and R 8 together form an aromatic bridge having a length of 3-5 atoms, where the atoms of the bridge are selected from the group comprising S, O, N and C, for example, = NON =;
in free form or in the form of a pharmaceutically acceptable acid addition salt. 9. Соединение, выбранное из группы, включающей
4-[2-(метокси)бифенил-5-ил]пиридин,
4-[2-(метокси)-3'-(нитро)бифенил-5-ил]пиридин,
4-[2-(метокси)-3'-(трифторметил)бифенил-5-ил]пиридин,
4-[2-(метокси)-3',4'-(пропилен)бифенил]пиридин,
4-[4-(метокси)-3-(бензофуразан-5-ил)фенил]пиридин,
4-[2-(метокси)-3'-(циан)бифенил-5-ил]пиридин,
4-[2-(метокси)-3'-(хлор)бифенил-5-ил]пиридин,
4-[2-(метокси)-3',4'-(метилендиокси)бифенил-5-ил]пиридин,
4-[2-(метокси)-3'-(фенокси)бифенил-5-ил]пиридин,
4-[2-(метокси)-4'-(фенокси)бифенил-5-ил]пиридин,
4-[2-(метокси)-3'-(хлор)-4'-(фтор)бифенил-5-ил]пиридин,
4'-метокси-3'-(бензофуразан-5-ил)[1,1'-бифенил]-4-карбоксамид,
этиловый эфир 4'-метокси-3'-(3-нитрофенил)[1,1'-бифенил] -4-карбоновой кислоты,
этиловый эфир 4'-метокси-3'-(3-нитрофенил)[1,1'-бифенил] -3-карбоновой кислоты,
этиловый эфир 4'-метокси-3-метил-3'-(3-нитрофенил)[1,1'-бифенил]-4-карбоновой кислоты,
этиловый эфир 3'-(5-бензофуразанил)-4'-метокси[1,1'-бифенил]-4-карбоновой кислоты,
2,2-диметилпропиловый эфир 3'-(5-бензофуразанил)-4'-метокси[1,1'-бифенил]-4-карбоновой кислоты,
3'-(5-бензофуразанил)-4'-метокси[1,1'-бифенил]-4-карбоновую кислоту,
4'-метокси-3'-(3-нитрофенил)[1,1'-бифенил]-3-карбоновую кислоту,
4'-метокси-3-метил-3'-(3-нитрофенил)[1,1'-бифенил]-4-карбоновую кислоту,
3'-(5-бензофуразанил)-4'-метокси[1,1'-бифенил]-4-карбоновую кислоту,
4'-метокси-3'-(3-хлорфенил)[1,1'-бифенил]-4-карбоновую кислоту,
4'-метокси-3'-(3-цианфенил)[1,1'-бифенил]-4-карбоновую кислоту,
4'-метокси-3'-(3-нитрофенил)[1,1'-бифенил]-4-карбоксамид,
4'-метокси-3'-(3-нитрофенил)[1,1'-бифенил]-3-карбоксамид,
4'-метокси-3-метил-3'-(3-нитрофенил)[1,1'-бифенил]-4-карбоксамид,
N-метил-4'-метокси-3'-(3-нитрофенил)[1,1'-бифенил]-4-карбоксамид,
6-[4-метокси-3-(5-бензофуразанил)фенил]имидазо[1,2-а]пиридин
в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли.9. A compound selected from the group consisting of
4- [2- (methoxy) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 '- (nitro) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 '- (trifluoromethyl) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 ', 4' - (propylene) biphenyl] pyridine,
4- [4- (methoxy) -3- (benzofurazan-5-yl) phenyl] pyridine,
4- [2- (methoxy) -3 '- (cyan) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 '- (chloro) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 ', 4' - (methylenedioxy) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 '- (phenoxy) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -4 '- (phenoxy) biphenyl-5-yl] pyridine,
4- [2- (methoxy) -3 '- (chlorine) -4' - (fluoro) biphenyl-5-yl] pyridine,
4'-methoxy-3 '- (benzofurazan-5-yl) [1,1'-biphenyl] -4-carboxamide,
4'-methoxy-3 '- (3-nitrophenyl) [1,1'-biphenyl] -4-carboxylic acid ethyl ester,
4'-methoxy-3 '- (3-nitrophenyl) [1,1'-biphenyl] -3-carboxylic acid ethyl ester,
4'-methoxy-3-methyl-3 '- (3-nitrophenyl) [1,1'-biphenyl] -4-carboxylic acid ethyl ester,
3 '- (5-benzofurazanyl) -4'-methoxy [1,1'-biphenyl] -4-carboxylic acid ethyl ester,
3'- (5-benzofurazanyl) -4'-methoxy [1,1'-biphenyl] -4-carboxylic acid 2,2-dimethylpropyl ester
3 '- (5-benzofurazanil) -4'-methoxy [1,1'-biphenyl] -4-carboxylic acid,
4'-methoxy-3 '- (3-nitrophenyl) [1,1'-biphenyl] -3-carboxylic acid,
4'-methoxy-3-methyl-3 '- (3-nitrophenyl) [1,1'-biphenyl] -4-carboxylic acid,
3 '- (5-benzofurazanil) -4'-methoxy [1,1'-biphenyl] -4-carboxylic acid,
4'-methoxy-3 '- (3-chlorophenyl) [1,1'-biphenyl] -4-carboxylic acid,
4'-methoxy-3 '- (3-cyanophenyl) [1,1'-biphenyl] -4-carboxylic acid,
4'-methoxy-3 '- (3-nitrophenyl) [1,1'-biphenyl] -4-carboxamide,
4'-methoxy-3 '- (3-nitrophenyl) [1,1'-biphenyl] -3-carboxamide,
4'-methoxy-3-methyl-3 '- (3-nitrophenyl) [1,1'-biphenyl] -4-carboxamide,
N-methyl-4'-methoxy-3 '- (3-nitrophenyl) [1,1'-biphenyl] -4-carboxamide,
6- [4-methoxy-3- (5-benzofurazanyl) phenyl] imidazo [1,2-a] pyridine
in free form or in the form of a pharmaceutically acceptable acid addition salt. 10. Способ получения соединения по любому из пп. 1 или 5-9, включающий взаимодействие соединения формулы I'а или формулы I'b:
Figure 00000005

Figure 00000006

где X обозначает галоген или уходящую группу, a R1, W и Az имеют значения, указанные в п. 8, с активированным арильным соединением формулы IIа или IIIа:
Figure 00000007

Figure 00000008

где Y обозначает галоген (предпочтительно бром) или уходящую группу, такую, как олово- или борсодержащую группу (предпочтительно -В(ОН)2), a R-группы имеют значения, указанные в п. 8, и выделение образовавшегося соединения в свободной форме или в форме фармацевтически приемлемой кислотно-аддитивной соли.10. The method of obtaining compounds according to any one of paragraphs. 1 or 5-9, including the interaction of the compounds of formula Ia or formula Ib:
Figure 00000005

Figure 00000006

where X denotes a halogen or leaving group, a R 1 , W and Az have the meanings indicated in paragraph 8, with an activated aryl compound of the formula IIa or IIIa:
Figure 00000007

Figure 00000008

where Y is halogen (preferably bromine) or a leaving group, such as a tin or boron group (preferably -B (OH) 2 ), a R-groups have the meanings indicated in paragraph 8, and the release of the resulting compound in free form or in the form of a pharmaceutically acceptable acid addition salt. 11. Соединение формул I'а или I'b
Figure 00000009

Figure 00000010

где Х обозначает галоген (предпочтительно бром) или уходящую группу, такую, как олово- или борсодержащую группу (предпочтительно -В(ОН)2), a R1 W и Az имеют значения, указанные в п. 8, при условии, что
когда Х обозначает бром и R1 обозначает метил, W не обозначает C-COOCH3,
когда Х обозначает хлор или бром и R1 обозначает метил, этил, пропил или бутил, W не обозначает С-СООН,
когда Х обозначает хлор и R1 обозначает метил, W не обозначает C-COOCH2CH3 или C-COOCH2CH2CH3 и,
когда R1 обозначает метил и Az обозначает замещенный хинолин или незамещенную или замещенную индольную группу, Х не обозначает фтор.11. Compound formulas of I'a or I'b
Figure 00000009

Figure 00000010

where X denotes halogen (preferably bromine) or a leaving group, such as a tin or boron group (preferably -B (OH) 2 ), a R 1 W and Az have the meanings indicated in paragraph 8, provided that
when X is bromine and R 1 is methyl, W is not C-COOCH 3 ,
when X is chlorine or bromine and R 1 is methyl, ethyl, propyl or butyl, W is not C-COOH,
when X is chlorine and R 1 is methyl, W is not C-COOCH 2 CH 3 or C-COOCH 2 CH 2 CH 3 and,
when R 1 is methyl and Az is substituted quinoline or an unsubstituted or substituted indole group, X is not fluorine. 12. Способ
а) понижающей регуляции или ингибирования выделения TNF-α,
б) ингибирования активности изофермента PDE типа IV,
в) осуществления иммуносупрессии,
г) лечения воспалительного заболевания, или
д) лечения любого конкретного состояния или заболевания, указанного выше,
у пациента, нуждающего в таком лечении, включающий введение пациенту эффективного количества агента по изобретению.12. Method
a) down regulation or inhibition of secretion of TNF-α,
b) inhibiting the activity of PDE isoenzyme type IV,
c) the implementation of immunosuppression,
d) treating an inflammatory disease, or
e) treating any particular condition or disease indicated above,
in a patient in need of such treatment, comprising administering to the patient an effective amount of an agent according to the invention.
RU98118568/04A 1996-03-08 1997-03-07 Triaryl compounds, method of their synthesis, pharmaceutical composition based on thereof, method of treatment and intermediates substances RU2194035C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9604926.7A GB9604926D0 (en) 1996-03-08 1996-03-08 Organic compounds
GB9604926.7 1996-03-08

Publications (2)

Publication Number Publication Date
RU98118568A true RU98118568A (en) 2000-10-10
RU2194035C2 RU2194035C2 (en) 2002-12-10

Family

ID=10790065

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98118568/04A RU2194035C2 (en) 1996-03-08 1997-03-07 Triaryl compounds, method of their synthesis, pharmaceutical composition based on thereof, method of treatment and intermediates substances

Country Status (24)

Country Link
US (4) US6090817A (en)
EP (1) EP0885193A1 (en)
JP (1) JP2001501582A (en)
KR (1) KR19990087592A (en)
CN (1) CN1216980A (en)
AR (1) AR006122A1 (en)
AU (1) AU721783B2 (en)
BR (1) BR9708011A (en)
CA (1) CA2249546A1 (en)
CO (1) CO4780025A1 (en)
CZ (1) CZ285098A3 (en)
GB (1) GB9604926D0 (en)
HU (1) HUP9902103A3 (en)
ID (1) ID16152A (en)
IL (1) IL125716A0 (en)
NO (1) NO984120L (en)
NZ (1) NZ331310A (en)
PE (1) PE55498A1 (en)
PL (1) PL328488A1 (en)
RU (1) RU2194035C2 (en)
SK (1) SK121698A3 (en)
TR (1) TR199801777T2 (en)
WO (1) WO1997032853A1 (en)
ZA (1) ZA972007B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
DE69810134T2 (en) 1997-09-23 2003-10-09 Astrazeneca Ab, Soedertaelje AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES BROUGHT BY CYTOKINS
JPH11209350A (en) 1998-01-26 1999-08-03 Eisai Co Ltd Nitrogen-containing heterocyclic derivative and medicine containing the same
HUP0102367A3 (en) 1998-05-15 2002-11-28 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
ATE282590T1 (en) 1998-05-15 2004-12-15 Astrazeneca Ab BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES
SK1762001A3 (en) 1998-08-04 2001-07-10 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
ATE254105T1 (en) * 1998-09-25 2003-11-15 Astrazeneca Ab BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
ATE232205T1 (en) 1998-10-01 2003-02-15 Astrazeneca Ab QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF DISEASES INVOLVING CYTOKINE
ATE266023T1 (en) 1999-03-17 2004-05-15 Astrazeneca Ab AMIDE DERIVATIVES
ATE320800T1 (en) 1999-08-21 2006-04-15 Altana Pharma Ag SYNERGISTIC COMBINATION OF ROFLUMILAST AND SALMETEROL
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
HUP0303181A2 (en) * 2001-02-12 2004-01-28 Merck Patent Gmbh. Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions suitable for treating of myocardial diseases
CA2468745A1 (en) * 2001-11-30 2003-06-12 The Burnham Institute Induction of apoptosis in cancer cells
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1624893A2 (en) 2003-04-01 2006-02-15 Applied Research Systems ARS Holding N.V. Inhibitors of phosphodiesterases in infertility
FR2856064B1 (en) * 2003-06-13 2005-08-19 Servier Lab NOVEL BENZOTHIAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
WO2005058280A2 (en) * 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
JP2007530566A (en) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド (R) -Enoximone sulfoxide and its use in the treatment of PDE-III mediated diseases
WO2005092332A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EP1758873A1 (en) * 2004-06-22 2007-03-07 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
BRPI0517500B8 (en) * 2004-12-23 2021-05-25 Galderma Res & Dev compound, use of a composition, pharmaceutical composition, cosmetic composition, non-therapeutic uses of a cosmetic composition, and cosmetic process to improve the appearance of the skin
MX369262B (en) 2005-02-16 2019-11-04 Anacor Pharmaceuticals Inc Boron-containing small molecules.
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
RU2452729C2 (en) * 2005-09-16 2012-06-10 Арроу Терапьютикс Лимитед Biphenyl derivatives and application thereof in treating hepatitis c
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2007078340A2 (en) 2005-12-30 2007-07-12 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN103479654B (en) 2006-02-16 2018-02-09 安纳考尔医药公司 Small molecule as the boracic of anti-inflammatory agent
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (en) 2006-05-09 2009-03-25 Braincells Inc 5 ht receptor mediated neurogenesis.
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (en) 2006-09-08 2009-07-10 Braincells Inc Combinations containing a 4-acylaminopyridine derivative.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2011504505A (en) * 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
JP2011505341A (en) * 2007-11-21 2011-02-24 デコード ジェネティクス イーエイチエフ Biaryl PDE4 inhibitors to treat inflammatory, cardiovascular and CNS disorders
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
EP2285384A4 (en) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
BRPI0922566A2 (en) * 2008-12-17 2017-03-28 Anacor Pharmaceuticals Inc crystalline polymorph, pharmaceutical composition, compound, and methods for preparing a compound, and for treating a disease.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8343944B2 (en) * 2009-07-28 2013-01-01 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
US9440994B2 (en) * 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060196A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
JP5952280B2 (en) 2010-09-07 2016-07-13 アナコール ファーマシューティカルズ，インコーポレーテッド Benzoxaborole derivatives for the treatment of bacterial infections
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2018081814A1 (en) * 2016-10-31 2018-05-03 University Of Kansas Grp94 selective inhibitors and uses thereof
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. Indane-amines as pd-l1 antagonists
CN109776445B (en) * 2019-03-28 2022-12-06 中国药科大学 Benzoxadiazole compound and its preparation method and medical application
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
CN112010882B (en) * 2019-05-31 2021-09-14 武汉大学 Method for stereoselectively preparing 3, 5-disubstituted cyclohexene compound and application
WO2021076688A1 (en) 2019-10-16 2021-04-22 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
CN111499566A (en) * 2020-04-30 2020-08-07 南京工业大学 Pyridine derivative compound and preparation method thereof
CN115466195B (en) * 2022-09-15 2024-04-19 中国科学院成都生物研究所 A type of biphenyl amide compound and its preparation method and application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1237895B (en) * 1963-10-03 1967-03-30 Adox Fotowerke Dr C Schleussne Spectrally sensitized silver halide photographic emulsion
CA2091989A1 (en) * 1990-09-28 1992-03-29 Roderick Alan Porter Phenylpyridinol derivatives as medicaments
DE4221583A1 (en) 1991-11-12 1993-05-13 Bayer Ag SUBSTITUTED BIPHENYLPYRIDONE
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
JP3802581B2 (en) * 1995-03-01 2006-07-26 富山化学工業株式会社 Novel biphenyl derivatives or salts thereof and anti-inflammatory agents containing them
FR2767525B1 (en) * 1997-08-21 1999-11-12 Cird Galderma BIPHENYL DERIVATIVES SUBSTITUTED BY AN AROMATIC OR HETEROAROMATIC RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
JP2002516305A (en) * 1998-05-12 2002-06-04 アメリカン・ホーム・プロダクツ・コーポレイション 2,3,5-Substituted biphenyls useful for treating insulin resistance and hyperglycemia

Similar Documents

Publication Publication Date Title
RU98118568A (en) TRIARY CONNECTIONS
RU2435771C2 (en) Spiroindolinone derivatives
EP0481676B1 (en) Hydroxyquinolone derivatives
KR20010031813A (en) Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CA2466560A1 (en) Acetylene derivatives having mglur5 antagonistic activity
RU96123280A (en) NITRO COMPOUNDS AND COMPOSITIONS ON THEIR BASIS, HAVING ANTI-INFLAMMATORY, ANALGETIC AND ANTI-THROMBOTIC ACTIVITY
RU93004423A (en) HINAZOLINE DERIVATIVE, METHOD FOR ITS OBTAINING, PHARMACEUTICAL COMPOSITION ON ITS BASIS AND APPLICATION
RU2009123525A (en) 5-SULFANILMETHyl [1,2,4} TRIAZOL [1,5-a] PYRIMIDIN-7-OLA DERIVATIVES AS CXCR2 ANTAGONISTS
RU2005137571A (en) NEW DERIVATIVES DIAZABICYCLONONENE
AU2001272597A1 (en) Coumarin derivatives with COMT inhibiting activity
WO2002002548A1 (en) Coumarin derivatives with comt inhibiting activity
RU97115107A (en) BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY
KR940009185A (en) Its use as pyrazolo [4,3-c] pyridine and serotonin reuptake inhibitor
EA007205B1 (en) Quinoline derivatives and use thereof as antitumor agents
RU2011102472A (en) SUBSTITUTED 7-SULFANILMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND THEIR APPLICATION
KR20140098710A (en) Biaryl or heterocyclic biaryl substituted cyclohexene derivatives compound for cetp inhibitor
US6525067B1 (en) Substituted heterocyclic derivatives
DK1242406T3 (en) Hitherto unknown compounds
RU2006126532A (en) BRONCHORELAXING COMPOUNDS
JP2003507469A (en) Fatty acid synthase inhibitors
RU2222541C2 (en) Optically active derivatives of pyrrolopyridazine, methods for their preparing, pharmaceutical composition and agent based on thereof, method for treatment or prophylaxis of ulcer disease
CN115724857B (en) Aromatic heterocyclic compound, pharmaceutical composition containing the same and application thereof
RU2004109817A (en) AMINOPYRROLEN DERIVATIVES AS ANTI-INFLAMMATORY PRODUCTS
CA2354605A1 (en) Diazabicyclooctane derivatives and therapeutic uses thereof
RU99113432A (en) NEW DERIVATIVES OF PHENANTRIDINIA